论文部分内容阅读
作为“国际制药企业协会联合会(IFPMA)的前经济政策总监韦伯博士(Dr.David E.Webber)通过对中国相关研究机构、政府部门和制药企业进行调查研究后得出的结论是:中国是最适合参与全球创新药品研发的发展中国家。那么,是哪些看不见的因素在背后发挥着作用,影响着新药研发,决定着是否有更多的创新药品能够成功上市呢?我们走访了现任阿斯利康制药有限公司医学及法规事务副总裁李昕威先生。详见第14版《市场·业界论坛》。
Dr. David E. Webber, former director of economic policy at the International Federation of Pharmaceutical Manufacturers Association (IFPMA), came to the conclusion that China is a research institute that conducted research on related research institutes, government departments and pharmaceutical companies in China. The most suitable for developing countries that participate in the global research and development of innovative drugs.Then, what are the invisible factors that play a role in the back, affecting the development of new drugs, determining whether more innovative drugs can be successfully listed? We visited the incumbent Mr. Li Xinwei, Vice President, Medical and Regulatory Affairs, Slideshow Pharmaceuticals Ltd. For more details, please refer to the 14th edition of the Market Forum.